

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan (MHRA-100690-PIP01-22-M01) and to the deferral

MHRA-100690-PIP01-22-M02

Scope of the Application

Active Substance(s)

IMIPENEM MONOHYDRATE; CILASTATIN SODIUM; RELEBACTAM MONOHYDRATE

Condition(s)

Treatment of infections caused by gram-negative organisms.

Pharmaceutical Form(s)

Powder for solution for infusion

Route(s) of Administration

INTRAVENOUS USE

Name / Corporate name of the PIP applicant

Merck Sharp & Dohme (UK) Limited

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Merck Sharp & Dohme (UK) Limited submitted to the licensing authority on 23/01/2024 21:36 GMT an application for a Modification

The procedure started on 15/03/2024 17:53 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100690-PIP01-22-M02

Of 06/06/2024 20:24 BST

On the adopted decision for IMIPENEM MONOHYDRATE; CILASTATIN SODIUM; RELEBACTAM MONOHYDRATE (MHRA-100690-PIP01-22-M02) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for IMIPENEM MONOHYDRATE; CILASTATIN SODIUM; RELEBACTAM MONOHYDRATE, Powder for solution for infusion , INTRAVENOUS USE .

This decision is addressed to Merck Sharp & Dohme (UK) Limited, 120 Moorgate, London, UNITED KINGDOM, EC2M 6UR

ANNEX I

1. Waiver

1.1 Condition:

Not applicable

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of infections caused by gram-negative organisms

2.2 Indication(s) targeted by the PIP:

Treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) Treatment of bacterial infections caused by aerobic gram-negative organisms in patients with limited treatment options

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

Powder for solution for infusion

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	2	Study 1 Dose range-finding juvenile toxicity study. Study 2 Definitive juvenile toxicity study.
Non-Clinical Studies	2	Study 3 (PN020) Open-label study to evaluate the pharmacokinetics, safety and tolerability of a single dose of imipenem/cilastatin/relebactam and to identify the appropriate dose in children from birth to less than 18 years of age with gram-negative bacterial infections. Study 4 (PN021) Open-label, randomised, active-controlled trial to evaluate safety, tolerability and efficacy of imipenem/cilastatin/relebactam in children from birth to less than 18 years of age with gram-negative bacterial infections. Study 5 was deleted during procedure EMEA-001809-PIP01-15-M01.
Clinical Studies	2	Study 6 (Modelling & Simulation Study) Modelling and simulation study to select doses in children from birth to less than 18 years of age with gram-negative bacterial infections. Study 7 (Extrapolation Study) Extrapolation study to evaluate the use of imipenem/cilastatin/relebactam in the proposed paediatric indications in children from birth to less than 18 years of age with serious gram-negative bacterial infections.

Extrapolation, Modeling & Simulation Studies	0	Not applicable.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/12/2024
Deferral of one or more studies contained in the paediatric investigation plan:	Yes